Surgical Science Sweden AB's EBIT per Share for the
three
months ended in Mar. 2026 was $0.05.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.14.
During the past 12 months, the average EBIT per Share Growth Rate of Surgical Science Sweden AB was -52.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -24.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 20.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Surgical Science Sweden AB's EBIT per Share or its related term are showing as below:
SUSRF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -24.9 Med: 55.85 Max: 85.6
Current: -24.9
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Surgical Science Sweden AB was 85.60% per year. The lowest was -24.90% per year. And the median was 55.85% per year.
SUSRF's 3-Year EBIT Growth Rate is ranked worse than 89.06% of 530
companies
in the Healthcare Providers & Services industry
Industry Median: 12
vs SUSRF: -24.90
Surgical Science Sweden AB (OTCPK:SUSRF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Surgical Science Sweden AB EBIT per Share Related Terms
Surgical Science Sweden AB EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB (SUSRF) has a EBIT per Share of $0.14 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Surgical Science Sweden AB and its competitors. According to the industry distribution chart, Surgical Science Sweden AB ranks #472 out of 530 companies in the Healthcare Providers & Services industry, placing it in the top 89.1%.
Is Surgical Science Sweden AB's EBIT per Share too high?
Surgical Science Sweden AB's current EBIT per Share is $0.14. The Healthcare Providers & Services industry median EBIT per Share is 12.00. Surgical Science Sweden AB's value of $0.14 is 98.8% below this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #472 out of 530 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Surgical Science Sweden AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #472 out of 530 companies for EBIT per Share. This places Surgical Science Sweden AB in the lower half of its industry. The industry median EBIT per Share is 12.00. Surgical Science Sweden AB's value of $0.14 is 98.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.00, based on 530 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current EBIT per Share of $0.14 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current EBIT per Share is $0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.30, compared to a current price of $4.00 — trading 72% below its estimated fair value. The current EBIT per Share is $0.14 and 98.8% below the Healthcare Providers & Services industry median of 12.00. Surgical Science Sweden AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current EBIT per Share is $0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 72% below its estimated GF Value™ of $14.30.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
EBIT per Share: $0.14
GF Value™: $14.30 vs. price of $4.00 (72% below fair value)
Industry Position: 98.8% below the Healthcare Providers & Services median (#472 of 530)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
82GF Score
Get the complete analysis for SUSRF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
